| Q40174727 | A Clinical and Pharmacokinetic Basis for the Selection and Use of Slow Release Theophylline Products |
| Q38235683 | Antiasthmatic therapy in children. |
| Q34458603 | Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing |
| Q40461043 | Evolving role of theophylline for treatment of chronic childhood asthma |
| Q67835419 | Impact of Rokitamycin, a New 16-Membered Macrolide, on Serum Theophylline |
| Q40467542 | Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation. |
| Q40094923 | Pharmacokinetic Drug Interactions with Theophylline |
| Q36648776 | Pharmacokinetic Interactions Between Theophylline and Other Medication (Part II) |
| Q35759081 | Pharmacokinetic drug interactions of macrolides |
| Q39814639 | Pharmacokinetic interactions of the macrolide antibiotics |
| Q69589903 | Spiramycin has no effect on serum theophylline in asthmatic patients |
| Q39525952 | Sustained release theophylline preparations. Practical recommendations for prescribing and therapeutic drug monitoring |
| Q71705865 | Sustained serum theophylline concentrations during chronic twice daily administration of a slow release preparation |
| Q38037883 | The effect of respiratory disorders on clinical pharmacokinetic variables |
| Q69501354 | [Pharmacokinetic interactions of macrolides and theophylline] |